Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
← catalyst calendarNCT07637734 · readout ≤ 377 d
Sponsored by Verrica Pharmaceuticals Inc. (industry) · VRCA — their whole pipeline →. With Torii Pharmaceutical Co. Ltd., CMIC Co, Ltd. Japan, Canfield Scientific Inc., Medidata Solutions and 3 more.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Common Warts
- Common Warts (Verruca Vulgaris)
- Human Papilloma Virus (HPV)
- Warts
Interventions
- Combination product: VP-102 (US) / TO-208 (Japan)
- Combination product: Vehicle (US) / Vehicle (Japan)
Primary outcome
what the primary-completion date above is the date OFProportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.
measured Day 84 (0/+8 days)
Permalink · VRCA's whole pipeline · Catalyst calendar · Every registered study · What changed